These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8141715)

  • 61. Tissue plasminogen activator (t-PA).
    Madhani J; Movsowitz H; Kotler MN
    Ther Drug Monit; 1993 Dec; 15(6):546-51. PubMed ID: 8122292
    [TBL] [Abstract][Full Text] [Related]  

  • 62. tPA fast by GUSTO.
    Horton R
    Lancet; 1993 May; 341(8854):1188. PubMed ID: 8098084
    [No Abstract]   [Full Text] [Related]  

  • 63. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
    Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
    J Am Coll Cardiol; 1994 Nov; 24(6):1445-52. PubMed ID: 7930274
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombolysis from P values to public health.
    Brophy JM
    Can J Cardiol; 1994 Dec; 10(10):997-9. PubMed ID: 7994669
    [No Abstract]   [Full Text] [Related]  

  • 65. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
    Al-Khatib SM; Stebbins AL; Califf RM; Lee KL; Granger CB; White HD; Armstrong PW; Topol EJ; Ohman EM;
    Am Heart J; 2003 Mar; 145(3):515-21. PubMed ID: 12660676
    [TBL] [Abstract][Full Text] [Related]  

  • 66. GUSTO, TIMI and the case for rapid reperfusion.
    Cannon CP; Braunwald E
    Acta Cardiol; 1994; 49(1):1-8. PubMed ID: 8184639
    [No Abstract]   [Full Text] [Related]  

  • 67. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
    Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
    Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM
    Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze.
    Zahn R; Rustige J; Koch A; Schiele R; Burczyk U; Schuster S; Harmjanz D; Boppert D; Gottwik M; Neuhaus KL; Senges J
    Am J Cardiol; 1997 Nov; 80(10):1339-43. PubMed ID: 9388110
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes.
    Brophy JM; Joseph L
    JAMA; 1995 Mar; 273(11):871-5. PubMed ID: 7869558
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular biology of plasminogen activators: what are the clinical implications of drug design?
    Smalling RW
    Am J Cardiol; 1996 Dec; 78(12A):2-7. PubMed ID: 8990404
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Mahaffey KW; Granger CB; Toth CA; White HD; Stebbins AL; Barbash GI; Vahanian A; Topol EJ; Califf RM
    J Am Coll Cardiol; 1997 Dec; 30(7):1606-10. PubMed ID: 9385883
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hirudin and Hirulog.
    White H
    Aust N Z J Med; 1993 Dec; 23(6):769-70. PubMed ID: 8141724
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
    Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
    Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Pilote L; Califf RM; Sapp S; Miller DP; Mark DB; Weaver WD; Gore JM; Armstrong PW; Ohman EM; Topol EJ
    N Engl J Med; 1995 Aug; 333(9):565-72. PubMed ID: 7623907
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thrombolysis in acute myocardial infarction: t-PA for everyone?
    Reeder GS; Kopecky SL
    Mayo Clin Proc; 1994 Aug; 69(8):796-9. PubMed ID: 8035639
    [No Abstract]   [Full Text] [Related]  

  • 79. Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.
    Réganon E; Ferrando F; Vila V; Villa P; Martínez-Sales V; Fayos L; Ruano M; Aznar J
    Haemostasis; 1998; 28(2):99-105. PubMed ID: 10087435
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.